Two Decades of Pioneering Innovation in CML and Beyond

Scientist checking samples

A Breakthrough for CML and Cancer Treatment

In May 2001 – exactly 20 years ago – Novartis received approval from the US Food and Drug Administration (FDA) for the first targeted therapy for cancer, known as a tyrosine kinase inhibitor (TKI). This was a watershed moment in drug discovery, transforming the treatment landscape for chronic …

/by

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

  • EMPATHY global multi-center Phase 2 – 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization
  • The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3
  • Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 – DARPin® antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 …
/by

Novartis receives FDA fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes

Novartis today announced that the US Food and Drug Administration (FDA) has granted fast track designation for sabatolimab (MBG453) in myelodysplastic syndromes (MDS). Fast track designation facilitates the development and expedites the review of drugs to treat serious conditions and fill unmet medical needs1.

  • MDS, a group of rare and often underdiagnosed blood cancers, is characterized by a dysfunctional immune system and leukemic stem cell proliferation2-4.
  • Despite treatment with HMAs – the last treatment innovation in higher-risk (HR) MDS over …
/by

One billion antimalarial treatments delivered: An extraordinary partnership journey

Child receives dispersible antimalarial treatment in Kenya

Who would have thought that an ancient Chinese herbal remedy would one day become the panacea for malaria? Sweet wormwood (Artemisia annua) was indeed used in traditional Chinese medicine for more than 2 000 …

/by

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

  • Overall survival and radiographic PFS from phase III study of investigational radioligand therapy 177Lu-PSMA-617 VISION trial of patients with metastatic castration-resistant prostate cancer to be presented at ASCO plenary
  • New Kisqali (ribociclib)* overall survival data from extended follow-up of MONALEESA-3 trial in patients with postmenopausal HR+/HER2- advanced or metastatic breast cancer
  • Phase II results for oral, targeted factor B inhibitor iptacopan (LNP023) as first line monotherapy in …
/by

Sandoz announces plans to further strengthen its antibiotics manufacturing setup in Europe

  • Sandoz to invest €150 million in new antibiotics manufacturing technology in Europe over next three to five years, to be optimally prepared for future needs

  • Kundl, Austria further strengthens production for oral antibiotics while facility in Palafolls, Spain expands for sterile active pharmaceutical ingredients

  • Investment affirms long-term confidence in antibiotics strategy, delivering and building on published plans for European-based manufacturing network

Basel, May 18, 2021 — …

/by

Novartis reaches milestone delivery of 1 billion courses of antimalarial treatment

  • Novartis has delivered 1 billion courses of antimalarial treatment, including 430 million pediatric treatments, largely at no profit since 1999
  • With other innovations, the Novartis artemisinin-based combination therapy (ACT) contributed to reduce malaria deaths by nearly half over the same timeframe1  
  • Novartis continues to invest in research and development for next-generation antimalarials to combat the threat of artemisinin resistance

The digital press …

/by

US Supreme Court denies Sandoz petition to review biosimilar Erelzi® (etanercept-szzs) case

  • Decision not to review Federal Circuit July 2020 ruling continues to prevent Sandoz launch of more affordable Erelzi treatment option for US patients
  • Sandoz is disappointed US patients affected by chronic autoimmune and inflammatory disease have to wait until 2029 for availability of biosimilar Erelzi
  • Sandoz remains committed to pioneering access for patients and contributing to more …
/by

World Asthma Day 2021

A family laugh together in the shade of a tree on a sunny day

Today is World Asthma Day, when people across the asthma community come together to raise awareness of the challenges being faced by millions of people living with asthma, their families, friends and caregivers. Asthma is a common condition, affecting approximately …

/by

Fighting MS through innovation

Amid the coronavirus pandemic, concern has grown over the potential neglect of other serious diseases. Multiple sclerosis (MS), for example, is a condition for which timely diagnosis, early treatment and the development of innovative therapies are particularly important for reducing the disabling progress of the disease. MS is the most common auto immune disorder to affect the central nervous system – that is, the brain and spinal cord. In many patients, the symptoms cause serious distress, increasingly diminishing their quality of life as their disability worsens. The average age of onset …

/by